| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Membrane Glycoproteins | 41 | 2024 | 62 | 10.680 |
Why?
|
| Endometrial Neoplasms | 9 | 2021 | 23 | 3.390 |
Why?
|
| Neovascularization, Pathologic | 9 | 2024 | 20 | 3.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2021 | 62 | 2.750 |
Why?
|
| Animals | 40 | 2024 | 1369 | 2.470 |
Why?
|
| Mice | 32 | 2024 | 555 | 2.350 |
Why?
|
| Glioblastoma | 4 | 2024 | 4 | 2.020 |
Why?
|
| Biomarkers, Tumor | 7 | 2024 | 30 | 1.980 |
Why?
|
| Breast Neoplasms | 4 | 2024 | 144 | 1.970 |
Why?
|
| Female | 34 | 2024 | 2964 | 1.840 |
Why?
|
| Humans | 49 | 2024 | 4931 | 1.840 |
Why?
|
| Precancerous Conditions | 6 | 2021 | 11 | 1.830 |
Why?
|
| Vascular Endothelial Growth Factor A | 8 | 2024 | 28 | 1.800 |
Why?
|
| Neoplasms | 3 | 2024 | 66 | 1.710 |
Why?
|
| Cell Line, Tumor | 15 | 2024 | 104 | 1.680 |
Why?
|
| Fetal Growth Retardation | 4 | 2019 | 35 | 1.420 |
Why?
|
| Antibodies, Monoclonal | 5 | 2024 | 23 | 1.370 |
Why?
|
| Placenta | 6 | 2024 | 37 | 1.360 |
Why?
|
| Membrane Proteins | 8 | 2023 | 22 | 1.330 |
Why?
|
| Macrophages | 2 | 2021 | 20 | 1.330 |
Why?
|
| Positron-Emission Tomography | 2 | 2024 | 6 | 1.310 |
Why?
|
| Brain Neoplasms | 4 | 2024 | 7 | 1.300 |
Why?
|
| Neoplastic Stem Cells | 2 | 2020 | 19 | 1.220 |
Why?
|
| Xenograft Model Antitumor Assays | 9 | 2024 | 28 | 1.220 |
Why?
|
| Endometrium | 4 | 2012 | 22 | 0.990 |
Why?
|
| Antineoplastic Agents | 6 | 2024 | 51 | 0.960 |
Why?
|
| Endothelial Cells | 2 | 2024 | 13 | 0.940 |
Why?
|
| Granzymes | 1 | 2024 | 1 | 0.930 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2024 | 8 | 0.930 |
Why?
|
| Zirconium | 1 | 2024 | 1 | 0.900 |
Why?
|
| Radioisotopes | 1 | 2024 | 2 | 0.900 |
Why?
|
| Focal Adhesion Kinase 1 | 7 | 2015 | 8 | 0.870 |
Why?
|
| Oxygen | 4 | 2024 | 33 | 0.850 |
Why?
|
| src-Family Kinases | 4 | 2014 | 6 | 0.850 |
Why?
|
| Signal Transduction | 8 | 2024 | 162 | 0.830 |
Why?
|
| Endometrial Hyperplasia | 2 | 2021 | 2 | 0.830 |
Why?
|
| Cell Proliferation | 6 | 2024 | 101 | 0.800 |
Why?
|
| Immunoglobulin G | 3 | 2017 | 10 | 0.790 |
Why?
|
| Mice, Nude | 7 | 2024 | 34 | 0.760 |
Why?
|
| Killer Cells, Natural | 2 | 2021 | 34 | 0.750 |
Why?
|
| Decidua | 1 | 2021 | 1 | 0.720 |
Why?
|
| Histocompatibility, Maternal-Fetal | 1 | 2021 | 1 | 0.720 |
Why?
|
| Mice, Inbred BALB C | 9 | 2020 | 34 | 0.710 |
Why?
|
| Molecular Targeted Therapy | 4 | 2017 | 9 | 0.700 |
Why?
|
| Retinal Pigment Epithelium | 7 | 2022 | 7 | 0.690 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 13 | 0.670 |
Why?
|
| Adenocarcinoma | 3 | 2012 | 28 | 0.650 |
Why?
|
| Pregnancy | 8 | 2024 | 417 | 0.650 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2019 | 2 | 0.630 |
Why?
|
| Disease Models, Animal | 6 | 2024 | 149 | 0.610 |
Why?
|
| Myelin Proteins | 3 | 2015 | 4 | 0.570 |
Why?
|
| Retinal Dehydrogenase | 1 | 2017 | 3 | 0.560 |
Why?
|
| Isoenzymes | 1 | 2017 | 10 | 0.550 |
Why?
|
| Hypoxia | 4 | 2022 | 30 | 0.550 |
Why?
|
| Placental Insufficiency | 1 | 2017 | 1 | 0.550 |
Why?
|
| Tetraspanins | 2 | 2015 | 2 | 0.530 |
Why?
|
| Apoptosis | 6 | 2024 | 117 | 0.500 |
Why?
|
| Tissue Distribution | 4 | 2024 | 22 | 0.490 |
Why?
|
| Gene Expression Profiling | 5 | 2019 | 34 | 0.470 |
Why?
|
| Mice, Inbred C57BL | 8 | 2024 | 196 | 0.450 |
Why?
|
| Air Pollutants | 2 | 2024 | 5 | 0.450 |
Why?
|
| Adult | 6 | 2021 | 1402 | 0.450 |
Why?
|
| Tissue Array Analysis | 5 | 2017 | 5 | 0.450 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2014 | 6 | 0.440 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2014 | 9 | 0.430 |
Why?
|
| Lung Neoplasms | 1 | 2014 | 34 | 0.420 |
Why?
|
| Immunoglobulin Fragments | 3 | 2012 | 3 | 0.420 |
Why?
|
| Molecular Imaging | 1 | 2013 | 1 | 0.410 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2013 | 2 | 0.410 |
Why?
|
| Retinopathy of Prematurity | 2 | 2024 | 2 | 0.390 |
Why?
|
| Retinal Neovascularization | 2 | 2024 | 2 | 0.390 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 2 | 2013 | 2 | 0.390 |
Why?
|
| RNA, Messenger | 8 | 2020 | 127 | 0.380 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 3 | 2022 | 5 | 0.380 |
Why?
|
| Protein Binding | 5 | 2011 | 21 | 0.370 |
Why?
|
| Cell Movement | 7 | 2019 | 24 | 0.370 |
Why?
|
| Middle Aged | 7 | 2021 | 1544 | 0.370 |
Why?
|
| Membrane Microdomains | 3 | 2011 | 4 | 0.360 |
Why?
|
| Integrin alpha6 | 1 | 2011 | 2 | 0.360 |
Why?
|
| Eukaryotic Initiation Factor-3 | 1 | 2010 | 1 | 0.350 |
Why?
|
| Prognosis | 4 | 2021 | 167 | 0.340 |
Why?
|
| Ovarian Neoplasms | 1 | 2010 | 34 | 0.340 |
Why?
|
| Aged | 5 | 2021 | 1188 | 0.340 |
Why?
|
| Cell Adhesion | 4 | 2011 | 17 | 0.330 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 407 | 0.330 |
Why?
|
| Blotting, Western | 9 | 2019 | 86 | 0.320 |
Why?
|
| Embryo Implantation | 2 | 2006 | 4 | 0.320 |
Why?
|
| Immunohistochemistry | 5 | 2017 | 98 | 0.310 |
Why?
|
| Neoplasms, Experimental | 1 | 2008 | 7 | 0.310 |
Why?
|
| Progesterone | 1 | 2008 | 10 | 0.290 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 3 | 2020 | 6 | 0.290 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2014 | 72 | 0.290 |
Why?
|
| Estradiol | 1 | 2008 | 47 | 0.290 |
Why?
|
| Epithelial Cells | 5 | 2019 | 36 | 0.280 |
Why?
|
| Disease Progression | 4 | 2024 | 137 | 0.280 |
Why?
|
| Corneal Neovascularization | 2 | 2019 | 2 | 0.270 |
Why?
|
| Antibodies, Blocking | 2 | 2019 | 2 | 0.250 |
Why?
|
| Flow Cytometry | 6 | 2014 | 41 | 0.250 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2005 | 1 | 0.250 |
Why?
|
| Cell Line | 9 | 2020 | 82 | 0.240 |
Why?
|
| Immunotherapy | 2 | 2019 | 13 | 0.240 |
Why?
|
| Caveolins | 2 | 2004 | 2 | 0.240 |
Why?
|
| Infant, Newborn | 2 | 2022 | 121 | 0.230 |
Why?
|
| Melanoma | 2 | 2016 | 7 | 0.230 |
Why?
|
| Skin Neoplasms | 2 | 2016 | 11 | 0.230 |
Why?
|
| Honey | 1 | 2024 | 2 | 0.230 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2024 | 5 | 0.230 |
Why?
|
| Epigenesis, Genetic | 1 | 2024 | 25 | 0.220 |
Why?
|
| Enzyme Activation | 3 | 2014 | 22 | 0.220 |
Why?
|
| Phenotype | 3 | 2024 | 62 | 0.220 |
Why?
|
| Glycosylphosphatidylinositols | 1 | 2004 | 1 | 0.220 |
Why?
|
| Gene Expression Regulation | 5 | 2019 | 83 | 0.220 |
Why?
|
| Collagen Type I | 4 | 2012 | 14 | 0.220 |
Why?
|
| Mice, Knockout | 2 | 2021 | 112 | 0.210 |
Why?
|
| Immune Tolerance | 2 | 2021 | 4 | 0.210 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2020 | 9 | 0.210 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2003 | 7 | 0.210 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2003 | 10 | 0.210 |
Why?
|
| Eye | 1 | 2003 | 9 | 0.210 |
Why?
|
| Extracellular Vesicles | 1 | 2023 | 2 | 0.210 |
Why?
|
| Retinal Pigments | 1 | 2022 | 1 | 0.200 |
Why?
|
| Transcriptome | 2 | 2019 | 15 | 0.200 |
Why?
|
| Neoplasm Metastasis | 2 | 2020 | 16 | 0.200 |
Why?
|
| Transfection | 2 | 2017 | 33 | 0.200 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2023 | 33 | 0.200 |
Why?
|
| Integrin alpha6beta1 | 1 | 2002 | 1 | 0.200 |
Why?
|
| Liver Neoplasms | 1 | 2023 | 51 | 0.190 |
Why?
|
| Pigment Epithelium of Eye | 3 | 2007 | 5 | 0.190 |
Why?
|
| Palatine Tonsil | 1 | 2002 | 1 | 0.190 |
Why?
|
| Cytological Techniques | 1 | 2002 | 2 | 0.190 |
Why?
|
| Tumor Cells, Cultured | 3 | 2020 | 58 | 0.190 |
Why?
|
| Phosphorylation | 4 | 2024 | 55 | 0.180 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 32 | 0.180 |
Why?
|
| Male | 5 | 2020 | 2620 | 0.180 |
Why?
|
| Immunity, Innate | 1 | 2021 | 13 | 0.180 |
Why?
|
| Models, Animal | 1 | 2021 | 17 | 0.180 |
Why?
|
| Antigens, CD34 | 2 | 2019 | 2 | 0.180 |
Why?
|
| Immunoprecipitation | 3 | 2011 | 10 | 0.170 |
Why?
|
| Green Fluorescent Proteins | 2 | 2017 | 6 | 0.170 |
Why?
|
| Trophoblasts | 2 | 2017 | 3 | 0.170 |
Why?
|
| Protein Transport | 3 | 2011 | 15 | 0.170 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2019 | 24 | 0.170 |
Why?
|
| Meningeal Neoplasms | 1 | 2020 | 1 | 0.170 |
Why?
|
| Meningioma | 1 | 2020 | 1 | 0.170 |
Why?
|
| Tetralogy of Fallot | 1 | 2019 | 1 | 0.170 |
Why?
|
| Heart Ventricles | 1 | 2019 | 15 | 0.160 |
Why?
|
| Vitreoretinopathy, Proliferative | 2 | 2011 | 2 | 0.160 |
Why?
|
| Protein Isoforms | 1 | 2019 | 2 | 0.160 |
Why?
|
| RNA, Small Interfering | 2 | 2017 | 21 | 0.160 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2019 | 22 | 0.150 |
Why?
|
| Up-Regulation | 2 | 2020 | 70 | 0.150 |
Why?
|
| Limbus Corneae | 2 | 2019 | 5 | 0.150 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2019 | 62 | 0.150 |
Why?
|
| Chlamydia muridarum | 2 | 2009 | 2 | 0.150 |
Why?
|
| Glioma | 1 | 2017 | 3 | 0.140 |
Why?
|
| Caveolin 1 | 3 | 2007 | 4 | 0.140 |
Why?
|
| Microarray Analysis | 1 | 2017 | 3 | 0.140 |
Why?
|
| Mice, SCID | 1 | 2017 | 8 | 0.140 |
Why?
|
| Homologous Recombination | 1 | 2017 | 1 | 0.140 |
Why?
|
| Fibrin | 1 | 2017 | 5 | 0.140 |
Why?
|
| Gene Knockout Techniques | 1 | 2017 | 3 | 0.140 |
Why?
|
| Pericytes | 2 | 2016 | 2 | 0.140 |
Why?
|
| Placentation | 1 | 2017 | 4 | 0.140 |
Why?
|
| Carcinogenesis | 1 | 2017 | 9 | 0.140 |
Why?
|
| Uterus | 1 | 2017 | 12 | 0.140 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 154 | 0.130 |
Why?
|
| Retrospective Studies | 2 | 2011 | 513 | 0.130 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2016 | 6 | 0.130 |
Why?
|
| Interleukin-10 | 1 | 2016 | 9 | 0.130 |
Why?
|
| Prenatal Nutritional Physiological Phenomena | 1 | 2016 | 14 | 0.130 |
Why?
|
| Fetal Nutrition Disorders | 1 | 2016 | 9 | 0.130 |
Why?
|
| Autophagy | 1 | 2016 | 11 | 0.130 |
Why?
|
| Microcirculation | 1 | 2016 | 10 | 0.130 |
Why?
|
| Retina | 2 | 2007 | 15 | 0.120 |
Why?
|
| Gene Expression | 2 | 2017 | 55 | 0.120 |
Why?
|
| Receptors, Cell Surface | 1 | 2015 | 23 | 0.120 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 10 | 0.120 |
Why?
|
| Maternal Exposure | 2 | 2024 | 9 | 0.110 |
Why?
|
| 3T3 Cells | 3 | 2003 | 12 | 0.110 |
Why?
|
| DNA Methylation | 2 | 2024 | 14 | 0.110 |
Why?
|
| Peroxynitrous Acid | 1 | 2014 | 2 | 0.110 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2014 | 4 | 0.110 |
Why?
|
| Extracellular Matrix | 2 | 2005 | 13 | 0.110 |
Why?
|
| Integrins | 2 | 2011 | 3 | 0.110 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2014 | 3 | 0.110 |
Why?
|
| Molecular Mimicry | 1 | 2013 | 1 | 0.110 |
Why?
|
| Copper Radioisotopes | 1 | 2013 | 1 | 0.100 |
Why?
|
| Protein Engineering | 1 | 2013 | 1 | 0.100 |
Why?
|
| Analysis of Variance | 1 | 2013 | 53 | 0.100 |
Why?
|
| Survival Analysis | 1 | 2013 | 85 | 0.100 |
Why?
|
| Microscopy, Confocal | 3 | 2012 | 9 | 0.100 |
Why?
|
| Hyperoxia | 2 | 2024 | 5 | 0.100 |
Why?
|
| Nuclear Proteins | 1 | 2012 | 9 | 0.100 |
Why?
|
| Animals, Newborn | 2 | 2024 | 76 | 0.100 |
Why?
|
| Transcription Factors | 1 | 2012 | 32 | 0.100 |
Why?
|
| Validation Studies as Topic | 1 | 2011 | 1 | 0.090 |
Why?
|
| Menstrual Cycle | 1 | 2011 | 9 | 0.090 |
Why?
|
| Tumor Burden | 1 | 2011 | 14 | 0.090 |
Why?
|
| Wound Healing | 1 | 2011 | 13 | 0.090 |
Why?
|
| Cells, Cultured | 3 | 2019 | 164 | 0.090 |
Why?
|
| Lymphoma, B-Cell | 2 | 2001 | 2 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2024 | 21 | 0.080 |
Why?
|
| Cell Membrane | 2 | 2007 | 35 | 0.080 |
Why?
|
| Immunoglobulins | 1 | 2009 | 4 | 0.080 |
Why?
|
| Genital Diseases, Female | 1 | 2009 | 3 | 0.080 |
Why?
|
| Chlamydia Infections | 1 | 2009 | 6 | 0.080 |
Why?
|
| Nerve Tissue Proteins | 2 | 2006 | 16 | 0.080 |
Why?
|
| Antibody Specificity | 1 | 2008 | 2 | 0.080 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2008 | 3 | 0.080 |
Why?
|
| RNA | 2 | 2014 | 18 | 0.080 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2008 | 13 | 0.070 |
Why?
|
| In Vitro Techniques | 1 | 2008 | 45 | 0.070 |
Why?
|
| NIH 3T3 Cells | 2 | 2007 | 5 | 0.070 |
Why?
|
| Down-Regulation | 2 | 2007 | 43 | 0.070 |
Why?
|
| Collagen | 1 | 2007 | 23 | 0.070 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2007 | 16 | 0.070 |
Why?
|
| Transcription, Genetic | 1 | 2007 | 28 | 0.070 |
Why?
|
| Disease-Free Survival | 1 | 2006 | 13 | 0.070 |
Why?
|
| Pilot Projects | 1 | 2006 | 53 | 0.060 |
Why?
|
| RNA, Catalytic | 1 | 2006 | 1 | 0.060 |
Why?
|
| Blastocyst | 1 | 2006 | 3 | 0.060 |
Why?
|
| Mice, Inbred Strains | 1 | 2006 | 20 | 0.060 |
Why?
|
| Survival Rate | 1 | 2006 | 92 | 0.060 |
Why?
|
| Fibronectins | 1 | 2005 | 5 | 0.060 |
Why?
|
| Epithelium | 1 | 2005 | 13 | 0.060 |
Why?
|
| Leptospermum | 1 | 2024 | 2 | 0.060 |
Why?
|
| 5-Methylcytosine | 1 | 2024 | 1 | 0.060 |
Why?
|
| MCF-7 Cells | 1 | 2024 | 8 | 0.060 |
Why?
|
| Intravitreal Injections | 1 | 2024 | 4 | 0.060 |
Why?
|
| Pulmonary Alveoli | 1 | 2004 | 5 | 0.060 |
Why?
|
| STAT3 Transcription Factor | 1 | 2024 | 15 | 0.060 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2024 | 13 | 0.060 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2024 | 21 | 0.060 |
Why?
|
| Fetal Development | 1 | 2024 | 21 | 0.060 |
Why?
|
| Adaptor Protein Complex gamma Subunits | 1 | 2004 | 1 | 0.060 |
Why?
|
| beta-Cyclodextrins | 1 | 2004 | 1 | 0.060 |
Why?
|
| Caveolin 2 | 1 | 2004 | 1 | 0.060 |
Why?
|
| Retroviridae | 1 | 2004 | 2 | 0.060 |
Why?
|
| Golgi Apparatus | 1 | 2004 | 2 | 0.060 |
Why?
|
| Molecular Chaperones | 1 | 2004 | 6 | 0.060 |
Why?
|
| Heat-Shock Proteins | 1 | 2004 | 8 | 0.060 |
Why?
|
| Transferrin | 1 | 2004 | 9 | 0.060 |
Why?
|
| Insulin Resistance | 1 | 2024 | 63 | 0.050 |
Why?
|
| Fetus | 1 | 2024 | 114 | 0.050 |
Why?
|
| G(M1) Ganglioside | 1 | 2003 | 1 | 0.050 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 2003 | 1 | 0.050 |
Why?
|
| Cell Communication | 1 | 2003 | 4 | 0.050 |
Why?
|
| Immunoblotting | 1 | 2003 | 10 | 0.050 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2003 | 7 | 0.050 |
Why?
|
| Lens Capsule, Crystalline | 1 | 2003 | 2 | 0.050 |
Why?
|
| Iris | 1 | 2003 | 3 | 0.050 |
Why?
|
| Cornea | 1 | 2003 | 4 | 0.050 |
Why?
|
| Antibodies | 1 | 2003 | 9 | 0.050 |
Why?
|
| Sclera | 1 | 2003 | 5 | 0.050 |
Why?
|
| Optic Nerve | 1 | 2003 | 10 | 0.050 |
Why?
|
| Glypicans | 1 | 2023 | 2 | 0.050 |
Why?
|
| Ciliary Body | 1 | 2003 | 7 | 0.050 |
Why?
|
| Electrocardiography | 1 | 2023 | 29 | 0.050 |
Why?
|
| Precipitin Tests | 1 | 2002 | 1 | 0.050 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2002 | 1 | 0.050 |
Why?
|
| Micromanipulation | 1 | 2002 | 1 | 0.050 |
Why?
|
| Lasers | 1 | 2002 | 9 | 0.050 |
Why?
|
| Specimen Handling | 1 | 2002 | 3 | 0.050 |
Why?
|
| Prostate-Specific Antigen | 1 | 2002 | 7 | 0.050 |
Why?
|
| Inflammation | 2 | 2016 | 122 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 66 | 0.050 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 2 | 2012 | 6 | 0.040 |
Why?
|
| Neoplasm Transplantation | 2 | 2016 | 14 | 0.040 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2000 | 18 | 0.040 |
Why?
|
| Drosophila Proteins | 1 | 2000 | 9 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2000 | 17 | 0.040 |
Why?
|
| Retinal Vessels | 1 | 2020 | 6 | 0.040 |
Why?
|
| E2F1 Transcription Factor | 1 | 2019 | 1 | 0.040 |
Why?
|
| Genome | 1 | 2019 | 4 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 5 | 0.040 |
Why?
|
| Wnt Proteins | 1 | 2019 | 10 | 0.040 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2019 | 11 | 0.040 |
Why?
|
| Infant | 1 | 2019 | 132 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2019 | 177 | 0.040 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2019 | 15 | 0.040 |
Why?
|
| Eye Burns | 1 | 2019 | 1 | 0.040 |
Why?
|
| Sodium Hydroxide | 1 | 2019 | 1 | 0.040 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2019 | 2 | 0.040 |
Why?
|
| Burns, Chemical | 1 | 2019 | 4 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2019 | 224 | 0.040 |
Why?
|
| Child | 1 | 2019 | 336 | 0.040 |
Why?
|
| Ki-67 Antigen | 1 | 2017 | 1 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 33 | 0.040 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 4 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2016 | 1 | 0.030 |
Why?
|
| Blood Vessels | 1 | 2016 | 3 | 0.030 |
Why?
|
| Mothers | 1 | 2016 | 11 | 0.030 |
Why?
|
| Energy Intake | 1 | 2016 | 22 | 0.030 |
Why?
|
| Luminescent Proteins | 1 | 2016 | 1 | 0.030 |
Why?
|
| Plasminogen Activator Inhibitor 2 | 1 | 2016 | 1 | 0.030 |
Why?
|
| Lectins | 1 | 2016 | 3 | 0.030 |
Why?
|
| Eating | 1 | 2016 | 28 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 2007 | 48 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 11 | 0.030 |
Why?
|
| Neural Crest | 1 | 2013 | 4 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2013 | 12 | 0.030 |
Why?
|
| Camptothecin | 1 | 2012 | 1 | 0.020 |
Why?
|
| Peptide Library | 1 | 2012 | 1 | 0.020 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2012 | 2 | 0.020 |
Why?
|
| Single-Chain Antibodies | 1 | 2012 | 2 | 0.020 |
Why?
|
| Thyroid Nuclear Factor 1 | 1 | 2012 | 1 | 0.020 |
Why?
|
| Menarche | 1 | 2012 | 1 | 0.020 |
Why?
|
| Menopause | 1 | 2012 | 4 | 0.020 |
Why?
|
| Age Factors | 1 | 2012 | 152 | 0.020 |
Why?
|
| Collagen Type IV | 1 | 2011 | 3 | 0.020 |
Why?
|
| Models, Biological | 1 | 2011 | 46 | 0.020 |
Why?
|
| Risk Factors | 1 | 2012 | 593 | 0.020 |
Why?
|
| Actins | 1 | 2009 | 15 | 0.020 |
Why?
|
| Colony Count, Microbial | 1 | 2009 | 1 | 0.020 |
Why?
|
| Cytokines | 1 | 2009 | 60 | 0.020 |
Why?
|
| Integrin alpha2 | 1 | 2008 | 1 | 0.020 |
Why?
|
| Integrin alpha1 | 1 | 2008 | 1 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2008 | 10 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2008 | 11 | 0.020 |
Why?
|
| Indoles | 1 | 2008 | 9 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2008 | 14 | 0.020 |
Why?
|
| Gels | 1 | 2007 | 4 | 0.020 |
Why?
|
| Lysosomes | 1 | 2007 | 8 | 0.020 |
Why?
|
| Proteasome Inhibitors | 1 | 2007 | 10 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2007 | 31 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2007 | 32 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2007 | 36 | 0.020 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-3 | 1 | 2004 | 3 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2004 | 176 | 0.010 |
Why?
|
| Rats | 1 | 2004 | 373 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2001 | 8 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 2001 | 6 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2001 | 8 | 0.010 |
Why?
|
| Genetic Therapy | 1 | 2001 | 11 | 0.010 |
Why?
|
| Insect Proteins | 1 | 2000 | 1 | 0.010 |
Why?
|
| Cdh1 Proteins | 1 | 2000 | 1 | 0.010 |
Why?
|
| Drosophila | 1 | 2000 | 3 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2000 | 9 | 0.010 |
Why?
|
| Base Sequence | 1 | 2000 | 35 | 0.010 |
Why?
|
| Cell Division | 1 | 2000 | 35 | 0.010 |
Why?
|